; and (B) written in plain language that consumers can readily understand. (3) Protected information Nothing in this section shall be construed to authorize the public disclosure of information submitted by a manufacturer that is prohibited from disclosure by applicable laws concerning the protection of trade secrets, commercial information, and other information covered under such laws. (f) Definition In this section, the term drug has the meaning given to such term in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 ). 5. Pricing requirements for existing treatments and vaccines in a public health emergency Title III of the Public Health Service Act is amended by inserting after section 319A ( 42 U.S.C. 247d–1a ) the following new section: 319B. Pricing requirements for treatments and vaccines in a public health emergency (a) Definitions For purposes of this section: (1) The term covered drug means a drug (including any vaccine) used to diagnose, mitigate, prevent, or treat a disease or disorder with respect to which there is or was in effect a declaration of a public health emergency under section 319. (2) The term covered period means the period ending if and when the circumstances which led to the public health emergency cease to exist and are unlikely to recur. (3) The term FDA-granted exclusivity means prohibitions on the submission or approval of drug applications granted under any of the following: (A) Clauses (ii) through (v) of section 505(c)(3)(E) of the Federal Food, Drug, and Cosmetic Act. (B) Subsection (j)(5)(B)(iv) or clause (ii), (iii), or (iv) of subsection (j)(5)(F) of such Act. (C) Section 505A of such Act. (D) Section 505E of such Act. (E) Section 527 of such Act. (F) Section 351(k)(7) of this Act. (G) Any other provision of law that provides for marketing or data exclusivity (or extension of exclusivity) with respect to a drug. (4) The term wholesale acquisition cost has the meaning given that term in section 1847A(c)(6)(B) of the Social Security Act. (b)